Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 6/20 | 0.66 |
| ▸ | MAOA | P21397 | 5/20 | 0.66 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.66 |
| ▸ | SDHA | P31040 | 2/20 | 0.66 |
| ▸ | LMNA | P02545 | 1/20 | 0.66 |
| ▸ | CALML3 | P27482 | 1/20 | 0.66 |
| ▸ | F10 | P00742 | 7/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5950128 | 0.94 | MAOB (0.67) | MAOBMAOAPTGS1SDHALMNA | |
| SCHEMBL5949692 | 0.94 | MAOB (0.66) | MAOBMAOAPTGS1SDHALMNA | |
| SCHEMBL5949833 | 0.93 | MAOB (0.67) | MAOBMAOAPTGS1SDHALMNA | |
| SCHEMBL5949871 | 0.92 | MAOB (0.66) | MAOBMAOAPTGS1SDHALMNA | |
| SCHEMBL5949620 | 0.92 | MAOB (0.63) | MAOBMAOAPTGS1SDHALMNA | |
| SCHEMBL5949802 | 0.92 | MAOB (0.63) | MAOBMAOAPTGS1SDHALMNA | |
| SCHEMBL5949467 | 0.92 | MAOB (0.63) | MAOBMAOAPTGS1SDHALMNA | |
| SCHEMBL5949723 | 0.91 | MAOB (0.65) | MAOBMAOAPTGS1SDHALMNA | |
| SCHEMBL5949890 | 0.91 | MAOB (0.62) | MAOBMAOAPTGS1SDHALMNA | |
| SCHEMBL5949537 | 0.91 | MAOB (0.62) | MAOBMAOAPTGS1SDHALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060229316-A1 | Novel antiinfective compounds, process for their preparation and pharmaceutical compositions containing them | CADILA HEALTHCARE LIMITED (IN) | 2006-10-12 | — | — | US | claimed |
| EP-1495021-A2 | ANTIINFECTVE COMPOUNDS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | CADILA HEALTHCARE LTD. (IN) | 2005-01-12 | — | — | EP | claimed |
| WO-2003082864-A2 | ANTIINFECTVE COMPOUNDS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | CADILA HEALTHCARE LIMITED (IN) | 2003-10-09 | — | — | WO | claimed |
| US-20060229316-A1 | Novel antiinfective compounds, process for their preparation and pharmaceutical compositions containing them | CADILA HEALTHCARE LIMITED (IN) | 2006-10-12 | — | — | US | disclosed |
| EP-1495021-A2 | ANTIINFECTVE COMPOUNDS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | CADILA HEALTHCARE LTD. (IN) | 2005-01-12 | — | — | EP | disclosed |
| WO-2003082864-A2 | ANTIINFECTVE COMPOUNDS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | CADILA HEALTHCARE LIMITED (IN) | 2003-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060229316-A1 | Novel antiinfective compounds, process for their preparation and pharmaceutical compositions containing them | VIP, ATG4B, ATG7 | MAOB 950/4885MAOA 1053/4885PTGS1 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.